SCHEMBL3453355

SCHEMBL3453355

COc1cc(OCC(=O)O)cc(OC)c1C=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
ERN1 O75460 1/20 0.51
POLB P06746 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 2/20 0.43
ALOX15 P16050 2/20 0.43
HPGD P15428 1/20 0.43
PTPRB P23467 1/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.42
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
TSHR P16473 1/20 0.42
FFAR1 O14842 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5556434 0.90 LMNA (0.57) LMNAERN1POLBSMN1; SMN2MEN1
SCHEMBL7285643 0.88 PTGDR2 (0.50) LMNAPOLBSMN1; SMN2HSD17B10ALOX15
SCHEMBL31429026 0.85 ALDH1A1 (0.54) LMNAERN1POLBMEN1KMT2A
SCHEMBL11109448 0.85 MAPT (0.43) LMNAERN1POLBSMN1; SMN2MEN1
SCHEMBL31562634 0.83 KDM4E (0.57) LMNAERN1POLBSMN1; SMN2MEN1
SCHEMBL421566 0.83 LMNA (0.49) LMNAERN1TSHRFFAR1PPARG
SCHEMBL1913198 0.81 PPARA (0.52) LMNAERN1FFAR1PPARGPPARD
SCHEMBL12049195 0.81 LMNA (0.54) LMNAPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL4635027 0.81 LMNA (0.54) LMNAPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL3292757 0.80 ALDH1A1 (0.63) LMNAPOLBSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166696-B2 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-01-23 US claimed
US-20040265899-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2004-12-30 US claimed
US-6787635-B2 azlactone-functionalized support such as a crosslinked polymer containing an alkenyl azlactone; use making combinatorial libraries 3M INNOVATIVE PROPERTIES COMPANY 2004-09-07 US claimed
EP-1373167-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M Innovative Properties Company (US) 2004-01-02 EP claimed
US-20020173051-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US claimed
WO-2002081078-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-10-17 WO claimed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-7820785-B2 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-10-26 US disclosed
US-20070049728-A1 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY 2007-03-01 US disclosed
US-7166696-B2 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-01-23 US disclosed
US-20040265899-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2004-12-30 US disclosed
US-6787635-B2 azlactone-functionalized support such as a crosslinked polymer containing an alkenyl azlactone; use making combinatorial libraries 3M INNOVATIVE PROPERTIES COMPANY 2004-09-07 US disclosed
EP-1373167-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M Innovative Properties Company (US) 2004-01-02 EP disclosed
US-20020173051-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
WO-2002081078-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173051-A1 Solid phase synthesis supports and methods FES, LSS, CCNK LMNA 1506/4885ERN1 1000/4885POLB 483/4885
US-20040265899-A1 Solid phase synthesis supports and methods FES, LSS, CCNK LMNA 1506/4885ERN1 1000/4885POLB 483/4885
US-20070049728-A1 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS FES, LSS, CCNK LMNA 1506/4885ERN1 1000/4885POLB 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.